Pergamon

Tetrahedron: *Asymmetry* 10 (1999) 4553–4561

TETRAHEDRON:
ASYMMETRY

Stereoselective synthesis of enantiomerically pure 4,5-disubstituted pyrrolidinones from -amino esters

Jianbo Wang,[a,] Yihua Hou,[a] Peng Wu,[a] Zhaohui Qu [a] and Albert S. C. Chan [b]

[a]*Department of Chemistry, Peking University, Beijing 100871, People's Republic of China*
[b]*Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong, People's Republic of China*

Received 25 October 1999; accepted 18 November 1999

Abstract

-Alkylation of *N*-tosyl-protected -amino esters with LDA as the base led to high *anti* selectivity for the newly formed C–C bond. The -alkylated -amino esters were further transformed to enantiomerically pure 4,5-disubstituted pyrrolidinones through hydrolysis, diazotization, and Wolf rearrangement under AgO_2CPh/Et_3N/dry THF conditions.

1. Introduction

The syntheses of enantiomerically pure pyrrolidin-2-ones with different substituents have attracted considerable attention from synthetic organic chemists in recent years, and a number of synthetic methodologies have been developed.[1] We have recently reported an efficient route to enantiomerically pure *N*-tosyl-protected 5-substituted pyrrolidin-2-ones **3**, starting from -amino acids.[2] The key step in this transformation is the intramolecular nucleophilic addition of the *N*-tosyl-protected amino group to the ketene, which is generated through the Wolff rearrangement[3,4] of the -diazo carbonyl group (Scheme 1).



Scheme 1.

Corresponding author. E-mail: wangjb@pku.edu.cn

0957-4166/99/$ - see front matter
PII: S0957-4166(99)00530-3

We envisaged that this approach might be extended to the synthesis of 4,5-disubstituted pyrrolidinones **6** through diastereoselective -alkylation of the *N*-tosyl-protected -amino esters **4** (Scheme 2). Here we wish to report the results of the investigation based on this consideration.



Scheme 2.

The key issue in this approach is the diastereoselective alkylation of *N*-tosyl-protected amino esters. The -alkylation of -amino esters has been studied by several groups, and their results suggest that high diastereoselectivity can be generally achieved.[5] Based on the results from these reports, we expected similarly high diastereoselectivity in the -alkylation of *N*-tosyl-protected amino esters, for which the -alkylation has not been previously studied. Thus, the *N*-tosyl-protected -amino methyl esters **4a** and **4b**, which were prepared from L-alanine and L-phenylalanine,[2] were deprotonated with 2.2 equivalents of LDA in anhydrous THF followed by the addition of halide. ^{1}H and ^{13}C NMR analysis of the crude products provided the ratio of the diastereoisomers **7** and **8**, and the results are summarized in Scheme 3. As shown in Scheme 3, the diastereoselectivity of the -alkylation is generally high. This is consistent with the results reported for the -alkylation of *N*-benzyloxycarbonyl (Cbz)[5g] or benzoyl[5a] protected -amino esters. The stereochemistry of the newly introduced stereogenic center was determined by chemical transformation to pyrrolidin-2-ones and ^{1}H NMR analysis (vide infra).



Scheme 3.

The major alkylation products together with their corresponding minor diastereoisomers, which are not separable by column chromatography from the major isomers, were purified by column chromatography. The alkylated esters were subjected to hydrolysis at room temperature to give acids. The acids were then converted into their corresponding -diazo carbonyls **9a–d** by the conventional procedure.[2,6] Finally, the Wolff rearrangement of the -diazo carbonyl compounds **9a–d** under the conditions that we reported previously (AgO_2CPh/Et_3N/dry THF)[2] led to the corresponding 4,5-disubstituted pyrrolidin-2-ones **10a–d** (Scheme 4). Column chromatography separation isolated a major product in each case. ^{1}H and ^{13}C NMR spectra of the products indicated that the disubstituted pyrrolidinones were single diastereoisomers in each case. It is known that the Wolff rearrangement proceeds with the retention of the configuration at the carbon where the migration occurs.[2,3c] The fact that single diastereoisomers of 4,5-disubstituted pyrrolidin-2-ones are obtained in high yields through the transformation from the alkylated -amino ester by hydrolysis, diazotization and the Wolff rearrangement suggests that the stereochemistry of the -alkyl group is retained during these transformations.

The stereochemistry of the newly introduced substituent at the 4-position was established by NOESY spectra of the pyrrolidin-2-ones. In the NOESY spectrum of pyrrolidinones **10a**, an NOE effect was



Scheme 4.

observed between the 5-Me group and 4-H, and the 4-Me group and 5-H, respectively. This suggests that the two methyl groups have *anti* configuration. The NOE spectrum of **10d** showed similar results (Fig. 1).



Fig. 1. NOE correlations in the NOESY spectra of **10a** and **10d**

From the stereochemistry of the 4,5-disubstituted pyrrolidinones, we can deduce that the major isomer of the -alkylation products was **7a**–**e**. This shows that alkylation with LDA as the base results in high *anti* selectivity. The *anti* selectivity has been generally observed in the -alkylation of -amino esters.[5] This selectivity can be reasonably interpreted by considering the chelation of a lithium ion between enolate oxygen and the deprotonated amino group. The chelated enolate prefers to take the half-chair conformation with the R group occupying a pseudo-axial position (Fig. 2). The alkylation takes place by the attack of electrophile from the opposite side of the neighboring R group, leading to the alkylation product with *anti* selectivity. To test if the stereochemistry is controlled by the presence of a chelation complex, we used *N*-sodium bis(trimethylsilyl)amide (NaHMDS) as the base in the alkylation reaction. It was expected that diastereoselectivity would decrease, since the sodium ion does not form a strong chelation complex with enolates. However, the alkylation with this base led only to an *N*-alkylated product; no trace -carbon alkylation product was obtained. The alkylation with LDA as the base in the presence of HMPA as co-solvent also led to the *N*-alkylation.



Fig. 2.

In conclusion, we have demonstrated that high diastereoselectivity could be achieved in the -alkylation of the *N*-tosyl-protected -amino esters. The -alkylated -amino esters can be easily transformed to 4,5-substituted pyrrolidin-2-ones in four steps. Since enantiomerically pure *N*-tosyl-protected -amino esters are easily available[7] and the stereochemistry of the amino group will stay unchanged in the reactions, this transformation should find application to the synthesis of enantiomerically pure polysubstituted pyrrolidin-2-ones in general.

2. Experimental

2.1. General

Melting points were determined in capillaries and are uncorrected. All reactions with air- and moisture-sensitive components were performed under a nitrogen atmosphere in a flame-dried reaction flask, and the components were added via syringe. All solvents were distilled prior to use. The boiling point of petroleum ether is between 30 and 60°C. THF was distilled from sodium prior to use. For chromatography, 100–200 mesh silica gel (Qingdao, China) was employed. For preparative TLC, 10–40 m silica gel GF254 (Qingdao, China) was used. Recrystallization was from petroleum ether–ethyl acetate. Diazomethane solution in dry ether was prepared from *N*-methyl-*N*-nitrosourea. ^{1}H and ^{13}C NMR spectra

13.88, 19.54, 21.41, 44.42, 51.55, 51.69, 126.90, 129.54, 138.37, 143.11, 174.92; MS (*m/z*, relative intensity) 286 (MH^+, 16), 285 (M^+, 0.5), 270 [(M Me)$^+$, 15), 198 (96), 155 (89), 91 (100). HRMS: calcd for M^+ $C_{13}H_{19}O_4NS$, 285.1035; found, 285.1027; calcd for MH^+ $C_{13}H_{20}O_4NS$, 286.1113; found, 286.1109.

2.3.2. N-*Tosyl-2(*S*)-benzyl-*L*- -homoalanine methyl ester **7b***

47%; M.p. 108–109°C; IR 3250 (NH), 2915, 1700 (C=O), 1410, 1315, 1200, 1140, 1065 cm ^{1}; ^{1}H NMR 1.02 (d, *J*=6.6 Hz, 3H), 2.41 (s, 3H), 2.62–2.90 (m, 3H), 3.55 (s, 3H), 3.51–3.65 (m, 1H), 5.42 (d, *J*=10.0 Hz, 1H), 7.05–7.27 (m, 5H), 7.29 (d, *J*=8.2 Hz, 2H), 7.77 (d, *J*=8.2 Hz, 2H); ^{13}C NMR (50 MHz) 20.64, 21.50, 35.57, 50.16, 51.68, 52.60, 126.58, 126.98, 128.49, 128.84, 129.67, 138.43, 138.79, 143.23, 174.25; MS (*m/z*, relative intensity) 361 (M^+, 7), 318 (4), 256 (5), 198 (38), 155 (51), 116 (33), 91 (100); anal calcd for $C_{19}H_{23}O_4NS$: C, 63.16; H, 6.37; N, 3.87; found: C, 62.86; H, 6.37; N, 3.64.

2.3.3. N-*Tosyl-2(*S*)-vinyl-*L*- -homoalanine methyl ester **7c***

71%; Oil; IR 3250 (NH), 2970, 1720 (C=O), 1420, 1320, 1145, 1080 cm ^{1}; ^{1}H NMR (400 MHz) 1.03 (d, *J*=6.8 Hz, 3H), 2.17–2.23 (m, 1H), 2.32–2.37 (m, 1H), 2.42 (s, 3H), 2.45–2.51 (m, 1H), 3.55–3.63 (m, 1H), 3.64 (s, 3H), 4.96 (d, br, *J*=4.0 Hz, 1H), 5.00 (s, 1H), 5.30 (d, *J*=9.6 Hz, 1H), 5.58–5.5.71 (m, 1H), 7.29 (d, *J*=8.1 Hz, 2H), 7.75 (d, *J*=8.1 Hz, 2H); ^{13}C NMR (100 MHz) 20.40, 21.45, 33.58, 50.00, 50.32, 51.68, 117.41, 126.93, 129.57, 134.48, 138.62, 143.16, 174.18; MS (*m/z*, relative intensity) 311 (M^+, 6), 296 [(M Me)$^+$, 22], 198 (100), 155 (96), 142 (46), 91 (194); HRMS calcd for M^+ $C_{15}H_{21}O_4NS$ 311.1191; found, 311.1201.

2.3.4. N-*Tosyl-2(*S*)-methyl-*L*- -homophenylalanine methyl ester **7d***

82%; Oil; IR 3275 (NH), 2920, 1720 (C=O), 1595, 1440, 1320, 1150 cm^{1}; ^{1}H NMR (400 MHz) 1.08 (d, *J*=7.2 Hz, 3H), 2.40 (s, 3H), 2.60–2.75 (m, 2H), 3.54–3.61 (m, 1H), 3.68 (s, 3H), 5.30 (s, 1H), 5.41 (d, *J*=8.9 Hz, 1H), 6.97–7.01 (m, 2H), 7.16–7.26 (m, 3H), 7.22 (d, *J*=8.5 Hz, 2H), 7.65 (d, *J*=8.5 Hz, 2H); ^{13}C NMR (50 MHz) 14.48, 21.42, 40.10, 40.67, 51.83, 57.65, 126.68, 126.87, 128.59, 129.13, 129.55, 137.19, 138.11, 143.05; MS (*m/z*, relative intensity) 362 (MH^+

[(M Me)$^+$, 9], 198 (69), 155 (70), 91 (100); anal. calcd for $C_{12}H_{17}NO_4S$: C, 53.14; H, 6.27; N, 5.17; found: C, 53.12; H, 6.31; N, 4.95.

2.3.7. N-*Tosyl-2(*S*)-benzyl-*L- *-homoalanine*

93%; Oil; IR 3235 (OH), 2930, 1680 (C=O), 1420, 1300, 1220, 1135, 1065 cm ^{1}; ^{1}H NMR (200 MHz) 1.04 (d, *J*=6.8 Hz, 3H), 2.41 (s, 3H), 2.70–3.10 (m, 3H), 3.60 (m, 1H), 5.60 (d, *J*=9.6 Hz, 1H), 7.05–7.20 (m, 2H), 7.22–7.30 (m, 3H), 7.29 (d, *J*=8.5 Hz, 2H), 7.77 (d, *J*=8.5 Hz, 2H); ^{13}C NMR (50 MHz) 20.32, 21.50, 34.99, 49.80, 52.47, 126.63, 127.03, 128.53, 128.90, 129.70, 138.27, 138.32, 143.42, 178.67; MS (*m/z*, relative intensity) 347 (M$^+$, 23), 301 (21), 256 [(M $C_6H_5CH_2$)$^+$, 7], 198 (44), 155 (46), 91 (100); HRMS calcd for $C_{18}H_{21}O_4NS$ 347.1191; found: 347.1183.

2.3.8. N-*Tosyl-2(*S*)-vinyl-*L- *-homoalanine*

96%; M.p. 110–112°C; IR 3230 (OH), 2950, 1690 (C=O), 1415, 1305, 1230, 1135, 1075 cm ^{1}; ^{1}H NMR (200 MHz) 1.07 (d, *J*=6.8 Hz), 2.22–2.76 (m, 3H), 2.42 (s, 3H), 2.53–3.70 (m, 1H), 4.96–5.04 (m, 1H), 5.07 (d, br, *J*=1.0 Hz, 1H), 5.45 (d, *J*=9.6 Hz, 1H), 5.62–5.79 (m, 1H), 7.30 (d, *J*=8.0 Hz, 2H), 7.76 (d, *J*=8.0 Hz, 2H); ^{13}C NMR (50 MHz) 20.26, 21.48, 33.35, 49.74, 50.22, 117.78, 127.00, 129.67, 134.33, 138.30, 143.37, 178.45; MS (*m/z*, relative intensity) 297 (M$^+$, 3), 282 [(M Me)$^+$, 19], 198 (71), 155 (80), 128 (35), 91 (100); anal. calcd for $C_{14}H_{19}NO_4S$: C, 56.55; H, 6.39; N, 4.71; found: C, 56.37; H, 6.39; N, 4.52.

2.3.9. N-*Tosyl-2(*S*)-methyl-*L- *-homophenylalanine*

91%; Oil; IR 3240 (OH), 2955, 1690 (C=O), 1585, 1440, 1400, 1240, 1140, 1070 cm ^{1}; ^{1}H NMR (200 MHz) 1.18 (d, *J*=7.2 Hz, 3H), 2.39 (s, 3H), 2.53–2.85 (m, 3H), 3.55–3.68 (m, 1H), 5.70 (d, *J*=8.8 Hz, 1H), 6.98–7.04 (m, 2H), 7.11–7.19 (m, 3H), 7.20 (d, *J*=8.1 Hz, 2H), 7.64 (d, *J*=8.1 Hz, 2H); ^{13}C NMR (50 MHz) 13.99, 21.44, 39.57, 40.77, 57.49, 126.65, 126.83, 128.58, 129.09, 129.59, 137.07, 137.61, 143.18, 180.03; MS (*m/z*, relative intensity) 256 [(M $C_6H_5CH_2$)$^+$, 46], 238 [(M $C_6H_5CH_2$ H_2O)$^+$, 7], 155 (36), 91 (100); HRMS calcd for (M $C_6H_5CH_2$)$^+$ $C_{11}H_{14}O_4NS$ 256.0643; found, 256.0640.

2.4. Typical procedure for the preparation of -diazo carbonyl compounds ***9a–d***

The acid (5 mmol) was dissolved in dry CH_2Cl_2 (20 mL) and the solution was cooled in an ice bath under N_2. To the solution was added dropwise oxalyl chloride (6 mmol) and 1 drop DMF. The solution was stirred for 3 h, during which time the temperature rose to about 25°C. The solvent and excess reagent were removed under reduced pressure. The acyl chloride thus obtained was dissolved in absolute THF (20 mL), and this solution was added dropwise to an ethereal solution of CH_2N_2 (15–20 mmol, 40 mL) at 0°C. The solution was stirred at between 0 and 25°C for 4 h. Solvent and excess reagent were removed under reduced pressure and the crude residue was purified by column chromatography with petroleum ether:EtOAc=3:1 as eluent.

*2.4.1. Diazo-[*N-*tosyl-2(*S*)-methyl-*L- *-homoalanyl]methane* ***9a***

59%; Oil; IR 3260 (NH), 2960, 2090 (C=N_2), 1615 (C=O), 1440, 1370, 1330, 1145, 1080 cm ^{1}; ^{1}H NMR (200 MHz) 1.05 (d, *J*=6.8 Hz, 3H), 1.07 (d, *J*=7.2 Hz, 3H), 2.41 (s, 3H), 2.32–2.50 (m, 1H), 3.41–3.55 (m, 1H), 5.24 (s, br, 1H), 5.50 (d, *J*=9.0 Hz, 1H), 7.28 (d, *J*=8.2 Hz, 2H), 7.74 (d, *J*=8.2 Hz, 2H); ^{13}C NMR (50 MHz) 14.57, 19.84, 21.43, 48.77, 52.29, 55.34, 126.89, 129.52, 138.48, 143.05, 197.24; MS (*m/z*, relative intensity) 265 (15), 252 [(M N_2 Me)$^+$, 2], 198 (38), 155 (68), 91 (100). HRMS calcd for (M N_2)$^+$ $C_{13}H_{17}NO_3S$ 267.0929; found, 267.0932.

*2.4.2. Diazo-[*N-*tosyl-2(*S*)-phenyl-*L*- -homoalanyl]methane* ***9b***

57%; Oil; IR 3245 (NH), 3080, 2055 (C=N_2), 1720, 1600, 1360, 1320, 1155, 1080 cm ^{1}; ^{1}H NMR (200 MHz) 1.05 (d, *J*=6.8 Hz, 3H), 2.40 (s, 3H), 2.49–2.96 (m, 3H), 3.60 (m, 1H), 4.95 (s, 1H), 5.88 (d, *J*=9.2 Hz, 1H), 7.02–7.10 (m, 2H), 7.13–7.31 (m, 3H), 7.28 (d, *J*=8.5 Hz, 2H), 7.77 (d, *J*=8.5 Hz, 2H); ^{13}C NMR (50 MHz) 20.49, 21.47, 36.17, 51.37, 56.07, 56.30, 126.92, 128.55, 128.90, 129.60, 131.10, 135.90, 138.50, 143.11, 196.79; MS (*m/z*, relative intensity) 343 [(M N_2)$^+$, 9], 279 (53), 252 [(M $C_6H_5CH_2$ N_2)$^+$, 75], 188 (64), 155 (100), 117 (75), 91 (98); HRMS calcd for (M N_2)$^+$ $C_{19}H_{21}O_3NS$ 343.1242; found, 343.1241.

*2.4.3. Diazo-[*N-*tosyl-2(*S*)-vinyl-*L*- -homoalanyl]methane* ***9c***

61%; Oil; IR 3240 (NH), 3080, 2960, 2090 (C=N_2), 1615 (C=O), 1340, 1320, 1150, 1080 cm ^{1}; ^{1}H NMR (200 MHz) 1.04 (d, *J*=6.8 Hz, 3H), 2.15–2.47 (m, 3H), 2.41 (s, 3H), 3.54–3.67 (m, 1H), 4.96 (d, *J*=6.6 Hz, 1H), 5.03 (s, 1H), 5.26 (s, br, 1H), 5.68–5.70 (m, 1H), 5.71 (d, *J*=9.6 Hz, 1H), 7.28 (d, *J*=8.0 Hz, 2H), 7.75 (d, *J*=8.0 Hz, 2H); ^{13}C NMR (50 MHz) 20.31, 21.43, 33.89, 50.84, 54.17, 56.90, 117.62, 126.87, 129.55, 134.56, 138.75, 143.06, 196.44; MS (*m/z*, relative intensity) 294 [(MH N_2)$^+$, 20], 251 (22), 229 (14), 214 (11), 198 (22), 155 (51), 91 (100). HRMS calcd for (M N_2)$^+$ $C_{15}H_{19}O_3NS$ 293.1085; found, 293.1084.

*2.4.4. Diazo-[*N-*tosyl-2(*S*)-methyl-*L*- -homophenylalanyl]methane* ***9d***

75%; M.p. 110–102°C; IR 3325 (NH), 2955, 2920, 2095 (C=N_2), 1720 (C=O), 1615, 1440, 1355, 1160, 1080 cm ^{1}; ^{1}H NMR (200 MHz) 1.05 (d, *J*=7.2 Hz, 3H), 2.39 (s, 3H), 2.60–2.81 (m, 3H), 3.50–3.62 (m, 1H), 5.16 (s, 1H), 5.89 (d, *J*=8.4 Hz, 1H), 6.98–7.08 (m, 2H), 7.18–7.28 (m, 5H), 7.67 (d, *J*=8.2 Hz, 2H); ^{13}C NMR (50 MHz) 15.43, 21.46, 40.28, 44.30, 55.61, 58.49, 126.65, 126.78, 128.64, 128.99, 129.53, 137.69, 138.48, 142.92, 185.12; MS (*m/z*, relative intensity) 343 [(M N_2)$^+$, 10], 328 [(M Me)$^+$, 13], 279 (94), 264 (38), 252 [(M $C_6H_5CH_2$)$^+$, 14], 188 (74), 155 (41), 91 (100); HRMS calcd for (M N_2)$^+$ $C_{19}H_{21}O_3NS$ 343.1242; found, 343.1244.

2.5. Typical procedure for the Wolff rearrangement of -diazo ketones

The -diazo ketone (1.0 mmol) was dissolved in absolute THF (10 mL). To the solution was added dropwise a solution of AgO_2CPh (0.13 mmol) in triethylamine (1.3 mL). The mixture was set to stir at room temperature for 2 h. The solvent was removed under reduced pressure and the crude residue was subjected to column chromatography with petroleum ether:EtOAc=4:1 as eluent.

*2.5.1. (*R*)-Methyl-5(*S*)-methyl-*N*-tosylpyrrolidin-2-one* ***10a***

94%; M.p. 124–125°C; [ ]$_D^{30}$=+39.7 (*c* 1.6, CH_2Cl_2); IR 2950, 1710 (C=O), 1340, 1195, 1150, 1070 cm ^{1}; ^{1}H NMR (200 MHz) 1.00 (d, *J*=6.8 Hz, 3H), 1.47 (d, *J*=6.2 Hz, 3H), 1.92 (m, 1H), 2.01 (m, 1H), 2.73 (q, *J*=8.4, 1H), 4.02 (qd, *J*=6.8, 1.0 Hz, 1H), 7.32 (d, *J*=8.6 Hz, 2H), 7.93 (d, *J*=8.6 Hz, 2H); ^{13}C NMR (50 MHz) 19.77, 21.05, 21.56, 33.98, 38.35, 63.65, 128.05, 129.41, 135.86, 144.84, 172.73; MS (*m/z*, relative intensity) 268 [(MH)$^+$, 22], 252 [(M Me)$^+$, 15], 203 (53), 188 (94), 155 (34), 91 (100%); anal. calcd for $C_{13}H_{17}O_3NS$: C, 58.41; H, 6.41; N, 5.24; found: C, 58.14; H, 6.40; N, 4.84.

*2.5.2. (*R*)-Benzyl-5(*S*)-methyl-*N*-tosylpyrrolidin-2-one* ***10b***

85%; Oil; [ ]$_D^{30}$=+67.6 (*c* 1.6, CH_2Cl_2); IR 2920, 1725 (C=O), 1595, 1440, 1350, 1160, 1080 cm ^{1}; ^{1}H NMR (400 MHz) 1.41 (d, *J*=6.5 Hz, 3H), 2.14 (dd, *J*=17.6, 1.8 Hz), 2.22–2.28 (m, 1H), 2.45 (s, 3H), 2.58 (dd, *J*=13.8, 7.7 Hz, 1H), 2.67 (dd, *J*=13.8, 8.3 Hz, 2H), 2.71 (dd, *J*=17.6, 7.9 Hz), 4.17 (qd,

J=6.4, 1.0 Hz, 1H), 7.05 (d, *J*=7.0 Hz, 2H), 7.04–7.32 (m, 3H), 7.35 (d, *J*=8.2 Hz, 2H), 7.95 (d, *J*=8.2 Hz, 2H); ^{13}C NMR 21.26, 21.61, 36.23, 39.72, 40.50, 60.76, 126.69, 128.13, 128.67, 128.78, 129.48, 135.87, 137.90, 144.97, 172.41; MS (*m/z*, relative intensity) 343 (10), 328 [(M Me)$^+$, 13], 279 (94), 264 (38), 252 [(M $C_6H_5CH_2$)$^+$, 14], 188 (74), 155 (41), 91 (100%); HRMS calcd M^+ $C_{19}H_{21}NO_3S$ 343.1242; found, 343.1223.

*2.5.3. (*R*)-Vinyl-5(*S*)-methyl*-N-*tosylpyrrolidin-2-one* ***10c***

84%; M.p. 53–54°C; [ ]$_D^{30}$=+50.2 (*c* 1.5, CH_2Cl_2); IR 2960, 2900, 1705 (C=O), 1345, 1155, 1065 cm ^{1}; ^{1}H NMR 1.47 (d, *J*=6.4 Hz, 3H), 2.01–2.13 (m, 4H), 2.44 (s, 3H), 2.64–2.79 (m, 1H), 4.16 (q, *J*=6.6 Hz, 1H), 5.03 (d, *J*=25.4 Hz, 1H), 5.04 (s, 1H), 5.55–5.72 (m, 1H), 7.33 (d, *J*=8.5 Hz, 2H), 7.93 (d, *J*=8.5 Hz, 2H); ^{13}C NMR (50 MHz) 21.47, 21.63, 36.22, 38.18, 38.42, 60.98, 118.29, 128.24, 129.47, 134.10, 135.93, 144.96, 172.53; MS (*m/z*, relative intensity) 294 (MH^+, 5), 229 (41), 200 (15), 187 (32), 155 (35), 91 (100); anal. calcd for $C_{15}H_{19}NO_3S$: C, 61.40; H, 6.53; N, 4.77; found: C, 61.38; H, 6.37; N, 4.59.

*2.5.4. (*R*)-Methyl-5(*S*)-benzyl*-N-*tosylpyrrolidin-2-one* ***10d***

85%; M.p. 148–150°C; [ ]$_D^{30}$=+80.6 (*c* 0.5, CH_2Cl_2); IR 2920, 2890, 1710 (C=O), 1440, 1335, 1145, 1095, 1070 cm ^{1}; ^{1}H NMR (200 MHz) 0.82 (d, *J*=6.8 Hz, 3H), 2.19–2.42 (m, 3H), 2.44 (s, 3H), 2.90 (dd, *J*=13.6, 9.0 Hz, 1H), 3.32 (dd, *J*=13.6, 3.4 Hz, 1H), 4.16 (dd, *J*=8.6, 3.4 Hz, 1H), 7.21–7.31 (m, 5H), 7.34 (2H, *J*=8.4 Hz, 2H), 7.97 (2H, *J*=8.4 Hz, 2H); ^{13}C NMR (50 MHz) 20.77, 21.65, 29.92, 38.29, 40.79, 68.34, 127.00, 128.26, 128.75, 129.43, 129.51, 135.68, 136.38, 145.06, 172.97; MS (*m/z*, relative intensity) 343 (M^+, 9), 252 [(M $C_6H_5CH_2$)$^+$, 73], 155 (61), 91 (100); anal. calcd for $C_{19}H_{21}NO_3S$: C, 66.45; H, 6.16; N, 4.08; found: C, 66.39; H, 6.12; N, 3.87.

Acknowledgements

Financial support by the Natural Science Foundation of China (Grant No. 29702002), State Education Commission of China and Peking University–Hong Kong Polytechnic University joint project on asymmetric synthesis is gratefully acknowledged. We also gratefully appreciate referees' comments on the interpretation of the origin of the diastereoselectivity.

References

1. For recent reports on the enantioselective synthesis of substituted pyrrolidin-2-ones, see: (a) Baussanne, I.; Royer, J. *Tetrahedron Lett.* **1998**, *39*, 845. (b) Ma, D.; Jiang, J. *Tetrahedron: Asymmetry* **1998**, *9*, 575. (c) Baussanne, I.; Travers, C.; Royer, J. *Tetrahedron: Asymmetry* **1998**, *9*, 797. (d) Wee, A. G. H.; Liu, B.; McLeod, D. D. *J. Org. Chem.* **1998**, *63*, 4218. (e) Anada, M.; Hashimoto, S.-i. *Tetrahedron Lett.* **1998**, *39*, 79. (f) Burgess, L. E.; Meyers, A. I. *J. Org. Chem.* **1992**, *57*, 1656.
2. Wang, J.; Hou, Y. *J. Chem. Soc., Perkin Trans. 1* **1998**, 1919.
3. For reviews on the Wolff rearrangement, see: (a) Doyle, M. P.; McKervey, M. A. *J. Chem. Soc., Chem. Commun.* **1997**, 983. (b) Ye, T.; McKervey, M. A. *Chem. Rev.* **1994**, *94*, 1091. (c) Meier, H.; Zell(e)15(y)65(,)-280(M.4.-;)-251(78 8.966 Tf 105.284 2 Td5(Asymmetr(P

Int. Ed. Engl. **1981**, *20*, 971. (d) Dener, J. M.; Zhang, L.-H.; Rapoport, H. *J. Org. Chem.* **1993**, *58*, 1159. (e) Fernandez-Megia, E.; Paz, M. M.; Sardina, F. J. *J. Org. Chem.* **1994**, *59*, 7643. (f) Humphery, J. M.; Bridges, R. J.; Hart, J. A.; Chamberlin, A. R. *J. Org. Chem.* **1994**, *59*, 2467. (g) Hanessian, S.; Margarita, R.; Hall, A.; Luo, X. *Tetrahedron Lett.* **1998**, *39*, 5883.

6. Ye, T.; McKervey, M. A. *Tetrahedron* **1992**, *48*, 8007.
7. Jefford, C. W.; Wang, J. *Tetrahedron Lett.* **1993**, *34*, 1111. (b) Jefford, C. W.; McNulty, J.; Lu, Z.-H.; Wang, J. *Helv. Chim. Acta* **1996**, *79*, 1203.